Korsana Biosciences, Inc. KRSA
Nov 10, 2026, 1:45 PM EST
- YTD
- +245.33%
- 1 year
- +143.65%
- Market cap
- 1.40B
- EPS (ttm)
- -16.14
- Shares out
- 45.54M
- Forward P/E
- -8.76
- YTD return
- +245.33%
- 1-year return
- +143.65%
- Volume
- 266.57K
- Avg volume
- 84.81K
- Open
- 31.00
- Previous close
- 31.17
- Day's range
- 30.00 – 32.30
- 52-week range
- 7.19 – 59.36
- Beta
- 1.84
- Analysts
- Strong Buy
- Price target
- 44.00 (+43.3%)
- Earnings date
- Mar 29, 2027
5D -0.60 (-1.89%)
Key statistics
- Enterprise value
- 228.77M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 134.16M
- Total debt
- 1.10M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 31.40
- 200-day average
- 22.49
Analyst view
Consensus: strong buy
- Target (low)
- 8.00
- Target (mean)
- 44.00
- Target (high)
- 70.00
- Strong buy0
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 29, 2027
Expected Mar 29, 2027. Consensus EPS estimate -1.13.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 29, 2027 | Dec 30, 2026 | -0.86 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -0.84695 | -3.19 | -2.34 | -276.65% |
| Aug 4, 2026 | Jun 30, 2026 | -3.45 | -0.41 | +3.04 | +88.12% |
| May 5, 2026 | Mar 31, 2026 | -2.66 | -2.66 | 0.00 | 0.00% |
| Mar 17, 2026 | Dec 31, 2025 | -2.66 | -1.75 | +0.91 | +34.21% |
| Nov 12, 2025 | Sep 30, 2025 | -121.80 | -0.30 | +121.50 | +99.75% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 2026 | Wedbush | init | — | Outperform |
| Sep 28, 2026 | Guggenheim | init | — | Buy |
| Sep 14, 2026 | Stifel | init | — | Buy |
| Sep 14, 2026 | TD Cowen | init | — | Buy |
| Sep 11, 2026 | UBS | init | — | Buy |
About Korsana Biosciences, Inc.
Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system. The company advances a pipeline of THETA-enabled therapeutics with an initial focus on neurodegenerative disorders. Its lead product candidate is KRSA-028, an anti-amyloid beta antibody for the treatment of Alzheimer's disease, which combines the THETA platform with elements of anti-amyloid beta approaches and targets a clinically relevant form of amyloid beta designed to improve brain uptake while reducing effects on reticulocytes. The company is also advancing a pipeline of additional THETA-enabled therapies for other neurodegenerative diseases. Korsana Biosciences, Inc. was incorporated in 2024 and is based in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- korsana.com
News
Korsana Biosciences Q3 EPS $(3.19) Misses $(0.85) Estimate 
Korsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update 
Wedbush Initiates Coverage On Korsana Biosciences with Outperform Rating, Announces Price Target of $44 
Guggenheim Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $70 - Stifel Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $43
- UBS Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $55
Your note
Sign in to keep a note on KRSA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHICKO RHONDA M. CPA | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 25,018 |
| GRAUL REGINA MARGARET | Chief Executive Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 107,523 |
| HECHT PETER M | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jul 15, 2026 | 910,312 |
| HIGGINS MICHAEL J | Director | Stock Award(Grant) | Mar 24, 2025 | 30,740 |
| SLATE PATH CAPITAL LP | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 20, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sanofi | 4.38% | 1,994,011 | 62.15M | Sep 29, 2026 |
| Kalehua Capital Management LLC | 0.52% | 235,907 | 7.35M | Jun 29, 2026 |
| FMR, LLC | 0.20% | 92,793 | 2.89M | Jun 29, 2026 |
| Balyasny Asset Management LP | 0.10% | 45,359 | 1.41M | Jun 29, 2026 |
| Adar1 Capital Management, LLC | 0.09% | 42,680 | 1.33M | Jun 29, 2026 |
| Braidwell LP | 0.05% | 22,413 | 698.61K | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.79% | 813,163 | 25.35M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.50% | 226,583 | 7.06M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 0.45% | 205,493 | 6.41M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 0.29% | 131,547 | 4.10M | Sep 29, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 0.14% | 65,364 | 2.04M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 0.11% | 51,518 | 1.61M | Sep 29, 2026 |